252 related articles for article (PubMed ID: 20585937)
1. Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study.
Pouwels S; Lalmohamed A; Souverein P; Cooper C; Veldt BJ; Leufkens HG; de Boer A; van Staa T; de Vries F
Osteoporos Int; 2011 Mar; 22(3):903-10. PubMed ID: 20585937
[TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.
Corley DA; Kubo A; Zhao W; Quesenberry C
Gastroenterology; 2010 Jul; 139(1):93-101. PubMed ID: 20353792
[TBL] [Abstract][Full Text] [Related]
3. Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting.
Cea Soriano L; Ruigómez A; Johansson S; García Rodríguez LA
Pharmacotherapy; 2014 Jun; 34(6):570-81. PubMed ID: 24634193
[TBL] [Abstract][Full Text] [Related]
4. Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis.
Vangala C; Niu J; Lenihan CR; Mitch WE; Navaneethan SD; Winkelmayer WC
Clin J Am Soc Nephrol; 2018 Oct; 13(10):1534-1541. PubMed ID: 30262672
[TBL] [Abstract][Full Text] [Related]
5. Long-term proton pump inhibitor therapy and risk of hip fracture.
Yang YX; Lewis JD; Epstein S; Metz DC
JAMA; 2006 Dec; 296(24):2947-53. PubMed ID: 17190895
[TBL] [Abstract][Full Text] [Related]
6. Association between proton pump inhibitors use and risk of hip fracture: A general population-based cohort study.
Wei J; Chan AT; Zeng C; Bai X; Lu N; Lei G; Zhang Y
Bone; 2020 Oct; 139():115502. PubMed ID: 32593677
[TBL] [Abstract][Full Text] [Related]
7. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study.
Freedberg DE; Haynes K; Denburg MR; Zemel BS; Leonard MB; Abrams JA; Yang YX
Osteoporos Int; 2015 Oct; 26(10):2501-7. PubMed ID: 25986385
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.
Poly TN; Islam MM; Yang HC; Wu CC; Li YJ
Osteoporos Int; 2019 Jan; 30(1):103-114. PubMed ID: 30539272
[TBL] [Abstract][Full Text] [Related]
9. Dopaminergic drugs and the risk of hip or femur fracture: a population-based case-control study.
Arbouw ME; Movig KL; van Staa TP; Egberts AC; Souverein PC; de Vries F
Osteoporos Int; 2011 Jul; 22(7):2197-204. PubMed ID: 20967420
[TBL] [Abstract][Full Text] [Related]
10. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate.
Lee J; Youn K; Choi NK; Lee JH; Kang D; Song HJ; Park BJ
J Gastroenterol; 2013 Sep; 48(9):1016-22. PubMed ID: 23307040
[TBL] [Abstract][Full Text] [Related]
11. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
Lin SM; Yang SH; Liang CC; Huang HK
Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotic use and the risk of hip/femur fracture: a population-based case-control study.
Pouwels S; van Staa TP; Egberts AC; Leufkens HG; Cooper C; de Vries F
Osteoporos Int; 2009 Sep; 20(9):1499-506. PubMed ID: 19156348
[TBL] [Abstract][Full Text] [Related]
13. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease.
Park JH; Lee J; Yu SY; Jung JH; Han K; Kim DH; Rhee J
BMC Geriatr; 2020 Oct; 20(1):407. PubMed ID: 33059626
[TBL] [Abstract][Full Text] [Related]
14. Use of anti-depressants and the risk of fracture of the hip or femur.
van den Brand MW; Pouwels S; Samson MM; van Staa TP; Thio B; Cooper C; Leufkens HG; Egberts AC; Verhaar HJ; de Vries F
Osteoporos Int; 2009 Oct; 20(10):1705-13. PubMed ID: 19238308
[TBL] [Abstract][Full Text] [Related]
15. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies.
Yu EW; Bauer SR; Bain PA; Bauer DC
Am J Med; 2011 Jun; 124(6):519-26. PubMed ID: 21605729
[TBL] [Abstract][Full Text] [Related]
16. Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands.
de Vries F; Souverein PC; Cooper C; Leufkens HG; van Staa TP
Calcif Tissue Int; 2007 Feb; 80(2):69-75. PubMed ID: 17308987
[TBL] [Abstract][Full Text] [Related]
17. Use of proton pump inhibitors and risk of pancreatic cancer.
Hicks B; Friis S; Pottegård A
Pharmacoepidemiol Drug Saf; 2018 Aug; 27(8):926-930. PubMed ID: 29923251
[TBL] [Abstract][Full Text] [Related]
18. The risk of bone fracture after long-term risperidone exposure is not increased compared to other atypical antipsychotics: A retrospective cohort study.
Shen SP; Liu Y; Qiu H; Tsai KY; Wu HC; Liang WM; Shu M; Chou FH
PLoS One; 2019; 14(9):e0221948. PubMed ID: 31487309
[TBL] [Abstract][Full Text] [Related]
19. Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region.
Reyes C; Formiga F; Coderch M; Hoyo J; Ferriz G; Casanovas J; Monteserín R; Brotons C; Rojas M; Moral I
Bone; 2013 Feb; 52(2):557-61. PubMed ID: 23023097
[TBL] [Abstract][Full Text] [Related]
20. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study.
Khalili H; Huang ES; Jacobson BC; Camargo CA; Feskanich D; Chan AT
BMJ; 2012 Jan; 344():e372. PubMed ID: 22294756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]